Reported 1 day ago
Needham has maintained its Buy rating for Recursion Pharmaceuticals (NASDAQ: RXRX), setting a price target of $8 following the company's positive second-quarter financial report for 2025. Recursion reported a revenue increase to $19.2 million, up from $14.4 million year-over-year, with substantial cash reserves of $534 million indicating financial stability. The company is focused on advancing its clinical development, particularly in cancer treatment.
Source: YAHOO